CLVS

Clovis Oncology Stock Price

6.32
0.03 (0.48%)
6.32

Low
4.08

52 Week Range

High
11.10

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Clovis Oncology Inc CLVS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 0.48% 6.32 08:00:04
Open Price Low Price High Price Close Price Prev Close
6.29
Bid Price Ask Price Spread News
6.30 6.32 0.02 - -
Trades Volume Avg Volume 52 Week Range
37 7,520 7,174,973 4.08 - 11.10
Last Trade Time Type Quantity Stock Price Currency
08:00:04 formt 450 $ 6.32 USD

Clovis Oncology Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 660.85M 104.56M 101.93M $ 164.52M $ - -4.44 -1.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 735.10k 1.80%

more financials information »

Clovis Oncology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CLVS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.016.305.766.055,108,2280.315.16%
1 Month5.227.245.105.919,016,7051.1021.07%
3 Months7.057.354.995.875,619,360-0.73-10.35%
6 Months4.9311.104.416.939,782,4801.3928.19%
1 Year7.1011.104.086.507,197,451-0.78-10.99%
3 Years48.1850.002.939.215,321,754-41.86-86.88%
5 Years12.9099.452.9317.113,928,773-6.58-51.01%

Clovis Oncology Description

Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.


Your Recent History
NASDAQ
CLVS
Clovis Onc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.